We author publications presenting our opinions, methodological approaches to health
products development, and our views on environment changes.

US&EU Regulations for drug delivery systems: development considerations for innovate products

SCRIP Regulatory Affairs

Marielle Fournier and Anne Dupraz-Poiseau describe US and EU rules governing prefilled syringes, pen injectors and innovative drug-delivery systems for biologics and consider the safety, quality and efficacy development challenges for manufacturers.

Hybrid or Mixed Marketing Authorization Application in the EU: not a trivial decision in new development programs for established drugs

Drug Information Journal

For any medicinal product Marketing Authorization Application (MAA) in the European Union, the applicant needs to indicate the legal basis for the application. This legal basis, laid down in Directive 2001/83/EC as amended, determines the dossier content, the market exclusivity, and the pediatric requirements in a significant way.

Biomarkers qualifications: a first step towards companion diagnostic development

SCRIP Regulatory Affairs

Biomarker qualification can be a first step towards companion diagnostic development. The European Medicines Agency already has a biomarker qualification process and the US Food and Drug Administration is developing one itself. The two agencies should find a way to harmonise their respective processes and propose clear incentives for companies seeking to use them.

Considerations on paediatric investigation plans for advanced therapy medicinal products,TOPRA Vol 8, No.10

Regulatory Rapporteur

In Europe, advanced therapy medicinal products (ATMPs) are subject to the requirements laid down in the Paediatric Regulation. A company developing an ATMP must therefore obtain agreement from the EMA on a paediatric investigation plan (PIP) or waiver prior to submitting its marketing authorisation application (MAA).

Telemedecine and E-health systems, (WPMC 2011 Workshop)


A long standing challenge for regulators has been how to incorporate new technologies into the current regulatory framework. This is especially applicable to telemedicine and e-health systems.

Activities to improve the regulatory framework for companion diagnostics step up

SCRIP Regulatory Affairs

Personalised medicine aims to provide the right treatment to the right patient, at the right dose and at the right time. this paper discusses how the regulatory process for companion diagnostics might be improved to realise the potential of personalised medicine.